Katarina Luptakova

CIK: 0001991149

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)2 (13.3%)

Derivative conversions

Awards (A)8 (53.3%)

Compensation grants

Other (G, F, J, C, D, …)5 (33.3%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

XLO

Xilio Therapeutics, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (15 total)

XLO
Xilio Therapeutics, Inc.
Jan 1, 2026
Exercise(M)
Direct
16.6K shares-
XLO
Xilio Therapeutics, Inc.
Dec 31, 2025
Award(A)
Stock Option (right to buy)
Direct
451.9K shares-
XLO
Xilio Therapeutics, Inc.
Nov 21, 2025
Disposition(D)
Stock Option (right to buy)
Direct
44.2K shares-
XLO
Xilio Therapeutics, Inc.
Nov 21, 2025
Award(A)
Stock Option (right to buy)
Direct
44.2K shares-
XLO
Xilio Therapeutics, Inc.
Nov 21, 2025
Disposition(D)
Stock Option (right to buy)
Direct
15K shares-
XLO
Xilio Therapeutics, Inc.
Nov 21, 2025
Award(A)
Stock Option (right to buy)
Direct
15K shares-
XLO
Xilio Therapeutics, Inc.
Nov 21, 2025
Award(A)
Stock Option (right to buy)
Direct
625K shares-
XLO
Xilio Therapeutics, Inc.
Nov 21, 2025
Disposition(D)
Stock Option (right to buy)
Direct
106K shares-
XLO
Xilio Therapeutics, Inc.
Nov 21, 2025
Award(A)
Stock Option (right to buy)
Direct
106K shares-
XLO
Xilio Therapeutics, Inc.
Nov 21, 2025
Disposition(D)
Stock Option (right to buy)
Direct
35K shares-
XLO
Xilio Therapeutics, Inc.
Nov 21, 2025
Award(A)
Stock Option (right to buy)
Direct
35K shares-
XLO
Xilio Therapeutics, Inc.
Nov 21, 2025
Disposition(D)
Stock Option (right to buy)
Direct
25K shares-
XLO
Xilio Therapeutics, Inc.
Nov 21, 2025
Award(A)
Stock Option (right to buy)
Direct
25K shares-
XLO
Xilio Therapeutics, Inc.
Jan 1, 2025
Exercise(M)
Direct
16.6K shares-
XLO
Xilio Therapeutics, Inc.
Jan 1, 2025
Award(A)
Stock Option (right to buy)
Direct
200K shares-

		Type	Shares	Price		Ownership
Jan 1, 2026	XLO Xilio Therapeutics, Inc.	Exercise(M)	16,625	-	$0	Direct
Dec 31, 2025	XLO Xilio Therapeutics, Inc.	Award(A) Stock Option (right to buy)	451,885	-	-	Direct
Nov 21, 2025	XLO Xilio Therapeutics, Inc.	Disposition(D) Stock Option (right to buy)	44,210	-	-	Direct
Nov 21, 2025	XLO Xilio Therapeutics, Inc.	Award(A) Stock Option (right to buy)	44,210	-	-	Direct
Nov 21, 2025	XLO Xilio Therapeutics, Inc.	Disposition(D) Stock Option (right to buy)	15,000	-	-	Direct
Nov 21, 2025	XLO Xilio Therapeutics, Inc.	Award(A) Stock Option (right to buy)	15,000	-	-	Direct
Nov 21, 2025	XLO Xilio Therapeutics, Inc.	Award(A) Stock Option (right to buy)	625,000	-	-	Direct
Nov 21, 2025	XLO Xilio Therapeutics, Inc.	Disposition(D) Stock Option (right to buy)	106,000	-	-	Direct
Nov 21, 2025	XLO Xilio Therapeutics, Inc.	Award(A) Stock Option (right to buy)	106,000	-	-	Direct
Nov 21, 2025	XLO Xilio Therapeutics, Inc.	Disposition(D) Stock Option (right to buy)	35,000	-	-	Direct
Nov 21, 2025	XLO Xilio Therapeutics, Inc.	Award(A) Stock Option (right to buy)	35,000	-	-	Direct
Nov 21, 2025	XLO Xilio Therapeutics, Inc.	Disposition(D) Stock Option (right to buy)	25,000	-	-	Direct
Nov 21, 2025	XLO Xilio Therapeutics, Inc.	Award(A) Stock Option (right to buy)	25,000	-	-	Direct
Jan 1, 2025	XLO Xilio Therapeutics, Inc.	Exercise(M)	16,625	-	$0	Direct
Jan 1, 2025	XLO Xilio Therapeutics, Inc.	Award(A) Stock Option (right to buy)	200,000	-	-	Direct

1-15 of 15 transactions

About Luptakova Katarina

Luptakova Katarina (SEC CIK 0001991149) files insider reports with the SEC as CHIEF MEDICAL OFFICER of Xilio Therapeutics, Inc. (XLO).

Signal8 holds 3 ownership filings by Luptakova Katarina, all Form 4s, filed between Jan 3, 2025 and Jan 5, 2026. Those filings report 15 transactions, from Jan 1, 2025 to Jan 1, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Luptakova Katarina's filings is in WALTHAM, MA.

Recent filings by Luptakova Katarina

Jan 1, 2026: Option exercise of XLO shares (Form 4, code M).
Dec 31, 2025: Grant or award of XLO derivative securities (Form 4, code A).
Nov 21, 2025: Disposition to issuer transaction of XLO derivative securities (Form 4, code D).
Nov 21, 2025: Grant or award of XLO derivative securities (Form 4, code A).
Nov 21, 2025: Disposition to issuer transaction of XLO derivative securities (Form 4, code D).

Other insiders filing for Xilio Therapeutics, Inc. (XLO)

Houvras Yariv, CHIEF MEDICAL OFFICER
Bello Akintunde Olatokumbo, Director
Shannon James Samuel, Director
Curran Daniel J., Director
Xu Yuan, Director
ROSS ROBERT W., Director

How to read Form 4 transaction codes